A price of $149/mo for compounded semaglutide includes shipping, supplies, nutrition, fitness, and BetterHelp built-in, plus a sturdy cold-chain delivery that arrived intact
The timing of discussion and adoption of possible legislation is a decision that will be made by each of three NCAA divisional governance structures
Before starting any GLP-1 medication, patients should undergo thorough medical evaluations to ensure these drugs are appropriate for their health conditions
Research has identified these alarming vision-related risks associated with GLP-1 medications: Sudden irreversible vision loss: NAION strikes without warning, often discovered upon waking, causing blurry or dim vision that progresses to immediate and permanent partial or complete blindness in the affected eye with no possibility of restoration Elevated risk across multiple studies: Beyond the Harvard findings showing 4-7 fold increased risk, a University of Southern Denmark study examining over 424,000 patients found weekly semaglutide users faced 2.19 times higher NAION risk European regulatory recognition: In June 2025, the European Medicines Agency officially recognized NAION as a possible side effect of semaglutide medications, marking formal acknowledgment by international regulators Complete absence of treatment options: Medical science currently offers no cure, no effective treatment, and no way to reverse NAION-related vision damage, leaving patients with permanent disability The permanent and irreversible nature of NAION-related optic nerve damage distinguishes these injuries from other complications that may resolve after discontinuing medication
It requires extensive Phase 3 trials before an FDA application can be submitted, meaning approval is likely several years away (estimates point to 20262027 at the earliest)
